Latest Cost Management News

The Calmer Co has reported a robust 26% increase in quarterly sales, driven by strong growth in Australia and the US, alongside a significant 39% reduction in cash used in operations, signaling clear progress toward profitability.

The Calmer Co. International Limited has delivered its strongest quarter yet, with revenue surging 26% to $2.4 million and operating cash outflows dropping to a historic low. Strategic growth across retail, e-commerce, and B2B channels underpins its confident path to breakeven.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Big River Industries reports a 4.9% sales decline year-to-date but highlights stabilizing revenue and resilient margins, with a cautious outlook on residential recovery and steady commercial demand.

BetMakers Technology Group kicks off FY26 with a strong financial turnaround and strategic advances, including a promising acquisition and digital wagering expansion in Nevada.

BetMakers Technology Group has reported a remarkable 361% growth in adjusted EBITDA for Q1 FY26, driven by strong revenue gains and operational efficiencies, while advancing its strategic expansion into the Las Vegas racing market.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 197% surge in net profit for the first nine months of 2025, driven by robust gold, nickel, and bauxite sales alongside strategic downstreaming and operational efficiencies.

Richmond Vanadium Technology reports solid progress in its Queensland vanadium project, advancing environmental approvals and feasibility studies while strengthening key industry collaborations.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.